ATLANTA, July 30, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.
(Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes
in the research, development and commercialization of prescription
ophthalmic pharmaceuticals, today announced that it will release its
second quarter fiscal year 2012 financial results after the market
close on Thursday, August 9, 2012. An investor conference call will
follow on the same day at 4:30 p.m. ET.

The conference call will be hosted by Dan Myers, President and Chief
Executive Officer, and Rick Eiswirth, Chief Operating Officer and Chief
Financial Officer.

To participate in the call, please dial (877) 369-6586 (U.S. and
Canada) or (253) 237-1165 (international). A live webcast will be
available on the Investor Relations section of the corporate website at
http://www.alimerasciences.com.

A replay of the conference call will be available beginning August 9,
2012 at 7:30 p.m. ET and ending on August 23, 2012 by dialing (855)
859-2056 (U.S. and Canada) or (404) 537-3406 (international),
Conference ID Number: 15550221. A replay of the webcast will be
available on the corporate website for two weeks, through August 23,
2012.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a
biopharmaceutical company that specializes in the research, development
and commercialization of prescription ophthalmic pharmaceuticals.
Presently Alimera is focused on diseases affecting the back of the eye,
or retina. Its primary product, ILUVIEN, is an intravitreal implant
containing fluocinolone acetonide (FAc), a non-proprietary
corticosteroid with demonstrated efficacy in the treatment of ocular
disease.


CONTACT: Investor Contact:
         ICR, LLC
         John Mills
         310-954-1105
         John.Mills@icrinc.com